Is Saffron Depression Meta-Analysis safe?

The current Migaku evidence database contains 2 reusable source documents for Saffron Depression Meta-Analysis. This answer focuses on safety, limits, and clinician-discussion contexts. - A Swiss study found that 10% of participants experienced PMS, whereas 3% experienced PMDD. [Mohammadi Mohammad Mehdi (2026); evidence level 1] - These challenges include legal issues, suicidal ideation, reduced work productivity, social isolation, parenting difficulties, increased absenteeism, disruptions of personal and social relationships, and frequent hospital visits. [Mohammadi Mohammad Mehdi (2026); evidence level 1] - PMS and dysmenorrhea can also contribute to increased susceptibility to accidents, drug addiction, financial losses, and diminished achievements []. [Mohammadi Mohammad Mehdi (2026); evidence level 1] - 1 2 2 3 1 4 5 6 Premenstrual syndrome (PMS) refers to a range of psychological, emotional and behavioral symptoms that occur prior to menstruation []. [Mohammadi Mohammad Mehdi (2026); evidence level 1] - This literature review synthesises evidence from randomised controlled trials, meta-analyses, safety data, dosing patterns, proposed mechanisms, and guideline positioning regarding saffron in depression, with a focus on adult major depressive disorder and related depressive symptomatology. [Dimech L (2026); evidence level 4] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.